Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.

Eveillard M, Rustad E, Roshal M, Zhang Y, Ciardiello A, Korde N, Hultcrantz M, Lu S, Shah U, Hassoun H, Smith E, Lesokhin A, Mailankody S, Landgren O, Thoren K.

Br J Haematol. 2020 Feb 5. doi: 10.1111/bjh.16443. [Epub ahead of print]

PMID:
32026474
2.

Correction: Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma.

Yellapantula V, Hultcrantz M, Rustad EH, Wasserman E, Londono D, Cimera R, Ciardiello A, Landau H, Akhlaghi T, Mailankody S, Patel M, Medina-Martinez JS, Ossa JEA, Levine MF, Bolli N, Maura F, Dogan A, Papaemmanuil E, Zhang Y, Landgren O.

Blood Cancer J. 2020 Jan 30;10(1):11. doi: 10.1038/s41408-020-0279-4.

3.

Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.

Salcedo M, Lendvai N, Mastey D, Schlossman J, Hultcrantz M, Korde N, Mailankody S, Lesokhin A, Hassoun H, Smith E, Shah U, Diab V, Werner K, Landau H, Lahoud O, Drullinsky P, Shah G, Chung D, Scordo M, Giralt S, Landgren O.

Clin Lymphoma Myeloma Leuk. 2019 Dec 26. pii: S2152-2650(19)32235-9. doi: 10.1016/j.clml.2019.12.013. [Epub ahead of print] No abstract available.

PMID:
32001193
4.

Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma.

Yellapantula V, Hultcrantz M, Rustad EH, Wasserman E, Londono D, Cimera R, Ciardiello A, Landau H, Akhlaghi T, Mailankody S, Patel M, Medina-Martinez JS, Arango Ossa JE, Levine MF, Bolli N, Maura F, Dogan A, Papaemmanuil E, Zhang Y, Landgren O.

Blood Cancer J. 2019 Dec 11;9(12):101. doi: 10.1038/s41408-019-0264-y. Erratum in: Blood Cancer J. 2020 Jan 30;10(1):11.

5.

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide.

Huang PA, Beedie SL, Chau CH, Venzon DJ, Gere S, Kazandjian D, Korde N, Mailankody S, Landgren O, Figg WD.

Sci Rep. 2019 Oct 16;9(1):14884. doi: 10.1038/s41598-019-51446-9.

6.

Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma.

Rustad EH, Misund K, Bernard E, Coward E, Yellapantula VD, Hultcrantz M, Ho C, Kazandjian D, Korde N, Mailankody S, Keats JJ, Akhlaghi T, Viny AD, Mayman DJ, Carroll K, Patel M, Famulare CA, Op Bruinink DH, Hutt K, Jacobsen A, Huang Y, Miller JE, Maura F, Papaemmanuil E, Waage A, Arcila ME, Landgren O.

Am J Hematol. 2019 Dec;94(12):1364-1373. doi: 10.1002/ajh.25641. Epub 2019 Oct 21.

PMID:
31571261
7.

Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.

Landgren O, Hofmann JN, McShane CM, Santo L, Hultcrantz M, Korde N, Mailankody S, Kazandjian D, Murata K, Thoren K, Ramanathan L, Dogan A, Rustad E, Lu SX, Akhlaghi T, Kristinsson SY, Björkholm M, Devlin S, Purdue MP, Pfeiffer RM, Turesson I.

JAMA Oncol. 2019 Jul 18. doi: 10.1001/jamaoncol.2019.1568. [Epub ahead of print]

PMID:
31318385
8.

BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy.

Smith EL, Mailankody S, Staehr M, Wang X, Senechal B, Purdon TJ, Daniyan AF, Geyer MB, Goldberg AD, Mead E, Santomasso BD, Landa J, Rimner A, Riviere I, Landgren O, Brentjens RJ.

Cancer Immunol Res. 2019 Jul;7(7):1047-1053. doi: 10.1158/2326-6066.CIR-18-0551. Epub 2019 May 21.

PMID:
31113804
9.

Many Shades of Disparities in Myeloma Care.

Ganguly S, Mailankody S, Ailawadhi S.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:519-529. doi: 10.1200/EDBK_238551. Epub 2019 May 17. Review.

10.

Outcomes of Oral Metronomic Therapy in Patients with Lymphomas.

Mailankody S, Ganesan P, Joshi A, Ganesan TS, Radhakrishnan V, Dhanushkodi M, Mehra N, Kalaiyarasi JP, Kannan K, Sagar TG.

Indian J Hematol Blood Transfus. 2019 Jan;35(1):50-56. doi: 10.1007/s12288-018-0995-0. Epub 2018 Aug 2.

11.

Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients.

Kazandjian D, Hill E, Hultcrantz M, Rustad EH, Yellapantula V, Akhlaghi T, Korde N, Mailankody S, Dew A, Papaemmanuil E, Maric I, Kwok M, Landgren O.

Blood Cancer J. 2019 Feb 4;9(2):15. doi: 10.1038/s41408-019-0177-9.

12.

Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial.

Kazandjian D, Korde N, Mailankody S, Hill E, Figg WD, Roschewski M, Landgren O.

JAMA Oncol. 2018 Dec 1;4(12):1781-1783. doi: 10.1001/jamaoncol.2018.5457. No abstract available.

13.

Addendum: Low-value approvals and high prices might incentivize ineffective drug development.

Prasad V, McCabe C, Mailankody S.

Nat Rev Clin Oncol. 2018 Dec;15(12):787. doi: 10.1038/s41571-018-0120-1.

PMID:
30420734
14.

Dietary intake is associated with risk of multiple myeloma and its precursor disease.

Thordardottir M, Lindqvist EK, Lund SH, Costello R, Burton D, Steingrimsdottir L, Korde N, Mailankody S, Eiriksdottir G, Launer LJ, Gudnason V, Harris TB, Landgren O, Torfadottir JE, Kristinsson SY.

PLoS One. 2018 Nov 1;13(11):e0206047. doi: 10.1371/journal.pone.0206047. eCollection 2018.

15.

Clarification of the FDA Accelerated Agnostic Approval of Pembrolizumab and the Opportunities Arising From the Required Confirmatory Studies-Reply.

Prasad V, Kaestner V, Mailankody S.

JAMA Oncol. 2018 Sep 1;4(9):1300-1301. doi: 10.1001/jamaoncol.2018.1715. No abstract available.

PMID:
29978197
16.

Low-value approvals and high prices might incentivize ineffective drug development.

Prasad V, McCabe C, Mailankody S.

Nat Rev Clin Oncol. 2018 Jul;15(7):399-400. doi: 10.1038/s41571-018-0030-2. No abstract available.

PMID:
29760505
17.

Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma.

Tageja N, Korde N, Kazandjian D, Panch S, Manasanch E, Bhutani M, Kwok M, Mailankody S, Yuan C, Stetler-Stevenson M, Leitman SF, Sportes C, Landgren O.

Bone Marrow Transplant. 2018 Nov;53(11):1445-1449. doi: 10.1038/s41409-018-0170-0. Epub 2018 May 4.

18.

Assessing Pharmaceutical Research and Development Costs-Reply.

Prasad V, Mailankody S.

JAMA Intern Med. 2018 Apr 1;178(4):588-589. doi: 10.1001/jamainternmed.2017.8737. No abstract available.

PMID:
29610885
19.

Money-Back Guarantees for Expensive Drugs: Wolf's Clothing but a Sheep Underneath.

Mailankody S, Bach PB.

Ann Intern Med. 2018 Jun 19;168(12):888-889. doi: 10.7326/M18-0539. Epub 2018 Apr 3. No abstract available.

PMID:
29610838
20.
21.

Most medical practices are not parachutes: a citation analysis of practices felt by biomedical authors to be analogous to parachutes.

Hayes MJ, Kaestner V, Mailankody S, Prasad V.

CMAJ Open. 2018 Jan 15;6(1):E31-E38. doi: 10.9778/cmajo.20170088.

22.

Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity.

Lendvai N, Tsakos I, Devlin SM, Schaffer WL, Hassoun H, Lesokhin AM, Landau H, Korde N, Mailankody S, Smith E, Chung DJ, Koehne G, Shah GL, Alexander A, Patel M, Ballagi A, Grundberg I, Giralt SA, Landgren O.

Leuk Lymphoma. 2018 Aug;59(8):1981-1985. doi: 10.1080/10428194.2017.1403020. Epub 2018 Jan 8. No abstract available.

23.

Vitamin D deficiency in patients with tuberculous meningitis and its relationship with treatment outcome.

Dangeti GV, Mailankody S, Neeradi C, Mandal J, Soundravally R, Joseph NM, Kamalanathan S, Swaminathan RP, Kadhiravan T.

Int J Tuberc Lung Dis. 2018 Jan 1;22(1):93-99. doi: 10.5588/ijtld.17.0304.

PMID:
29297432
24.

Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study.

Thordardottir M, Lindqvist EK, Lund SH, Costello R, Burton D, Korde N, Mailankody S, Eiriksdottir G, Launer LJ, Gudnason V, Harris TB, Landgren O, Kristinsson SY.

Blood Adv. 2017 Nov 1;1(24):2186-2192. doi: 10.1182/bloodadvances.2017007609. eCollection 2017 Nov 14.

25.

Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma.

Mailankody S, Kazandjian D, Korde N, Roschewski M, Manasanch E, Bhutani M, Tageja N, Kwok M, Zhang Y, Zingone A, Lamy L, Costello R, Morrison C, Hultcrantz M, Christofferson A, Washington M, Boateng M, Steinberg SM, Stetler-Stevenson M, Figg WD, Papaemmanuil E, Wilson WH, Keats JJ, Landgren O.

Blood Adv. 2017 Sep 29;1(22):1911-1918. doi: 10.1182/bloodadvances.2017005934. eCollection 2017 Oct 10.

26.

Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.

Palazzo M, Shah GL, Copelan O, Seier K, Devlin SM, Maloy M, Kenny S, Hassoun H, Korde NS, Lendvai N, Lesokhin AM, Mailankody S, Chung DJ, Koehne G, Landgren CO, Landau H, Giralt SA, Perales MA.

Biol Blood Marrow Transplant. 2018 Apr;24(4):871-876. doi: 10.1016/j.bbmt.2017.12.795. Epub 2017 Dec 27.

27.

Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers.

Prasad V, Kaestner V, Mailankody S.

JAMA Oncol. 2018 Feb 1;4(2):157-158. doi: 10.1001/jamaoncol.2017.4182. No abstract available. Erratum in: JAMA Oncol. 2018 Oct 1;4(10):1439.

PMID:
29285544
28.

Clinically meaningful benefit: real world use compared against the American and European guidelines.

Dreicer JJ, Mailankody S, Fakhrejahani F, Prasad V.

Blood Cancer J. 2017 Dec 14;7(12):645. doi: 10.1038/s41408-017-0009-8. No abstract available.

29.

Overall Survival vs Disease-Specific Survival-Reply.

Mailankody S, Prasad V.

JAMA Oncol. 2018 Apr 1;4(4):586-587. doi: 10.1001/jamaoncol.2017.3865. No abstract available. Erratum in: JAMA Oncol. 2018 Oct 1;4(10):1439.

PMID:
29167883
30.

CAR T cell therapy for multiple myeloma: where are we now and where are we headed?

Ghosh A, Mailankody S, Giralt SA, Landgren CO, Smith EL, Brentjens RJ.

Leuk Lymphoma. 2018 Sep;59(9):2056-2067. doi: 10.1080/10428194.2017.1393668. Epub 2017 Nov 6. Review.

31.

Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey.

Landgren O, Graubard BI, Kumar S, Kyle RA, Katzmann JA, Murata K, Costello R, Dispenzieri A, Caporaso N, Mailankody S, Korde N, Hultcrantz M, Therneau TM, Larson DR, Cerhan JR, Rajkumar SV.

Blood Cancer J. 2017 Oct 20;7(10):e618. doi: 10.1038/bcj.2017.97.

32.

Affordable Care Act, Health Insurance Coverage, and Cancer Outcomes.

Mailankody S.

J Clin Oncol. 2017 Dec 10;35(35):3893-3894. doi: 10.1200/JCO.2017.75.4259. Epub 2017 Oct 16. No abstract available.

PMID:
29035644
33.

Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.

Prasad V, Mailankody S.

JAMA Intern Med. 2017 Nov 1;177(11):1569-1575. doi: 10.1001/jamainternmed.2017.3601. Erratum in: JAMA Intern Med. 2017 Nov 1;177(11):1703. Erratum in: JAMA Intern Med. 2018 Oct 1;178(10):1433.

34.

A further strategy to combat the high price of anticancer drugs.

Prasad V, De Jesús K, Mailankody S.

Nat Rev Clin Oncol. 2017 Oct;14(10):629. doi: 10.1038/nrclinonc.2017.137. Epub 2017 Aug 22. No abstract available.

PMID:
28829055
35.

Host-related immunodeficiency in the development of multiple myeloma.

Dosani T, Mailankody S, Korde N, Manasanch E, Bhutani M, Tageja N, Roschewski M, Kwok M, Kazandjian D, Costello R, Burton D, Zhang Y, Liewehr D, Steinberg SM, Maric I, Landgren O.

Leuk Lymphoma. 2018 May;59(5):1127-1132. doi: 10.1080/10428194.2017.1361026. Epub 2017 Aug 9.

36.

Cerebrospinal fluid matrix metalloproteinase 9 levels, blood-brain barrier permeability, and treatment outcome in tuberculous meningitis.

Mailankody S, Dangeti GV, Soundravally R, Joseph NM, Mandal J, Dutta TK, Kadhiravan T.

PLoS One. 2017 Jul 12;12(7):e0181262. doi: 10.1371/journal.pone.0181262. eCollection 2017.

37.

Circulating Adiponectin Levels Differ Between Patients with Multiple Myeloma and its Precursor Disease.

Hofmann JN, Mailankody S, Korde N, Wang Y, Tageja N, Costello R, Zingone A, Hultcrantz M, Pollak MN, Purdue MP, Landgren O.

Obesity (Silver Spring). 2017 Aug;25(8):1317-1320. doi: 10.1002/oby.21894. Epub 2017 Jun 11.

38.

Pharmaceutical Marketing for Rare Diseases: Regulating Drug Company Promotion in an Era of Unprecedented Advertisement.

Mailankody S, Prasad V.

JAMA. 2017 Jun 27;317(24):2479-2480. doi: 10.1001/jama.2017.5784. No abstract available. Erratum in: JAMA. 2018 Jul 24;320(4):409. JAMA. 2018 Jul 24;320(4):408.

PMID:
28520871
39.

Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms.

Sissung TM, Peer CJ, Korde N, Mailankody S, Kazandjian D, Venzon DJ, Landgren O, Figg WD.

Cancer Chemother Pharmacol. 2017 Jul;80(1):217-221. doi: 10.1007/s00280-017-3323-8. Epub 2017 May 9.

40.

Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance.

Hassoun H, Roshal M, Sabari J, Nguyen J, Gao Q, Devlin SM, Landau H, Lendvai N, Chung DJ, Lesokhin AM, Korde N, Mailankody S, Dogan A, Giralt SA, Landgren CO.

Leuk Lymphoma. 2017 Dec;58(12):2962-2965. doi: 10.1080/10428194.2017.1312382. Epub 2017 May 9. No abstract available.

PMID:
28482750
41.

The high price of anticancer drugs: origins, implications, barriers, solutions.

Prasad V, De Jesús K, Mailankody S.

Nat Rev Clin Oncol. 2017 Jun;14(6):381-390. doi: 10.1038/nrclinonc.2017.31. Epub 2017 Mar 14. Review.

PMID:
28290490
42.

Controversies in multiple myeloma: Evidence-based update.

Ahn IE, Mailankody S.

Semin Oncol. 2016 Dec;43(6):666-675. doi: 10.1053/j.seminoncol.2016.10.006. Epub 2016 Nov 2. Review.

PMID:
28061984
43.

Proteomic profiling in plasma cell disorders: a feasibility study.

Mailankody S, Devlin SM, Korde N, Lendvai N, Lesokhin A, Landau H, Hassoun H, Ballagi A, Ekman D, Chung DJ, Patel M, Koehne G, Giralt S, Landgren O.

Leuk Lymphoma. 2017 Jul;58(7):1757-1759. doi: 10.1080/10428194.2016.1258699. Epub 2016 Dec 2. No abstract available.

44.

Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World.

Mailankody S, Prasad V.

JAMA Oncol. 2017 Jul 1;3(7):889-890. doi: 10.1001/jamaoncol.2016.5296. No abstract available.

PMID:
27892992
45.

Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia.

Mailankody S, Landgren O.

Best Pract Res Clin Haematol. 2016 Jun;29(2):187-193. doi: 10.1016/j.beha.2016.08.015. Epub 2016 Sep 4. Review.

PMID:
27825465
46.

Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency.

Ogunniyi A, Rodriguez M, Devlin S, Adel N, Landau H, Chung DJ, Lendvai N, Lesokhin A, Koehne G, Mailankody S, Korde N, Reich L, Landgren O, Giralt S, Hassoun H.

Leuk Lymphoma. 2017 May;58(5):1123-1129. doi: 10.1080/10428194.2016.1239261. Epub 2016 Oct 13.

47.

The Rising Price of Cancer Drugs-A New Old Problem?

Prasad V, Wang R, Afifi SH, Mailankody S.

JAMA Oncol. 2017 Feb 1;3(2):277-278. doi: 10.1001/jamaoncol.2016.4275. No abstract available.

PMID:
27711927
48.

Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood.

Murata K, McCash SI, Carroll B, Lesokhin AM, Hassoun H, Lendvai N, Korde NS, Mailankody S, Landau HJ, Koehne G, Chung DJ, Giralt SA, Ramanathan LV, Landgren O.

Clin Biochem. 2018 Jan;51:66-71. doi: 10.1016/j.clinbiochem.2016.09.015. Epub 2016 Sep 21.

49.

Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.

Landgren O, Devlin S, Boulad M, Mailankody S.

Bone Marrow Transplant. 2016 Dec;51(12):1565-1568. doi: 10.1038/bmt.2016.222. Epub 2016 Sep 5.

50.

Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies.

Mailankody S, Prasad V.

Oncologist. 2016 Sep;21(9):1031-2. doi: 10.1634/theoncologist.2016-0086. Epub 2016 Jul 8. No abstract available.

Supplemental Content

Loading ...
Support Center